Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Johnson and Johnson
Dow
AstraZeneca
Harvard Business School

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Alemtuzumab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for alemtuzumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Northwestern UniversityPhase 2
M.D. Anderson Cancer CenterPhase 1
Isaac Tunez-FiƱanaPhase 1/Phase 2

See all alemtuzumab clinical trials

Recent Litigation for alemtuzumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
CELGENE CORPORATION v. SANDOZ INC.2018-06-26

See all alemtuzumab litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Forty Seven, Inc.2016-08-08
Forty Seven, Inc.2016-08-05

See all alemtuzumab litigation

Pharmacology for alemtuzumab

Company Disclosures: US Patents for alemtuzumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Burroughs Wellcome Co. (Research Triangle Park, NC) 2014-08-05 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial British Technology Group Limited (London, GB) 2015-12-08 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial BTG International Limited (London, GB) 2020-05-27 RX Orphan company
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for alemtuzumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for alemtuzumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2016 020 Romania   Start Trial PRODUCT NAME: ALEMTUZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/13/869; DATE OF NATIONAL AUTHORISATION: 20130912; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/869; DATE OF FIRST AUTHORISATION IN EEA: 20130912
2019 00007 Denmark   Start Trial PRODUCT NAME: TISAGENLECLEUCEL; REG. NO/DATE: EU/1/18/1297 20180827
138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
C00105 Luxembourg   Start Trial PRODUCT NAME: KYMRIAH - TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
C00104 Luxembourg   Start Trial PRODUCT NAME: KYMRIAH - TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
2015 00043 Denmark   Start Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
Moodys
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.